Fig. 2

Correlation analysis of the 25-lncRNA risk signature with HCC early recurrence in the training cohort. A) The 150 HCC patients in the training cohort was ranked according to their risk scores from low to high, and the median risk score was set as the cut-off to divide the 150 HCC patients into low-risk group (n = 75) and high-risk group (n = 75); B) The 25-lncRNA expression profile in the 150 HCC patients. The 19 risk lncRNAs were enriched in the high-risk group and the 6 protective lncRNAs were enriched in the low-risk group; C) 81.25% and 76.06% HCC patients with recurrence in 1-year and 2-year respectively were classified in the high-risk group, and 18.72% and 23.94% HCC patients with recurrence in 1-year and 2-year respectively were classified in the low-risk group (P = 0.005)